圣湘生物(688289)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
华安证券 2024-01-24 买入
中邮证券 2023-12-18 买入
  盈利预测
据圣湘生物三季报分析:

  盈利能力明显恶化,主营业务利润贡献大幅下降

  成长能力明显恶化,公司规模由扩张变为收缩

  偿债能力维持稳定,偿还流动负债能力很强

  运营能力明显恶化,产品市场竞争力明显减弱

  现金流能力明显恶化,现金满足投资能力被严重削弱

  财务数据
    截至第三季度实现净利润2.98亿元,每股收益0.51元。

    截至第三季度最新股东权益742908.28万元,未分配利润512592.77万元。

    截至第三季度最新总资产830776.37万元,负债87868.09万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入632,543,388.93427,695,798.2195,173,984.726,450,356,637.86
营业总成本649,562,487.47432,733,363.67208,212,898.933,908,293,410.02
营业利润366,331,155.03111,377,767.2471,852,760.922,339,809,462.07
利润总额352,123,142.95108,045,667.9770,437,043.942,315,921,580.59
净利润298,485,079.7690,920,733.8559,989,487.461,936,706,879.02
其他综合收益-8,530,070.973,757,379.64-2,094,022.13-2,529,970.79
综合收益总额289,955,008.7994,678,113.4957,895,465.331,934,176,908.23
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计6,086,682,981.246,263,941,916.67,049,797,308.087,525,436,285.14
非流动资产合计2,221,080,746.551,978,619,359.151,677,257,425.561,648,325,798.6
资产总计8,307,763,727.798,242,561,275.758,727,054,733.649,173,762,083.74
流动负债合计771,773,768.27912,976,671.11,087,834,786.91,571,725,748.35
非流动负债合计106,907,167.1681,818,594.1364,976,658.889,263,740.65
负债合计878,680,935.43994,795,265.231,152,811,445.71,660,989,489
归属于母公司股东权益合计7,414,741,960.747,232,942,079.647,562,110,642.187,500,616,529.33
股东权益合计7,429,082,792.367,247,766,010.527,574,243,287.947,512,772,594.74
负债和股东权益合计8,307,763,727.798,242,561,275.758,727,054,733.649,173,762,083.74
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计1,350,241,899.62996,770,481.17567,398,702.136,493,768,113.71
经营活动现金流出小计1,519,821,792.741,113,467,970.97685,282,497.783,934,821,190.36
经营活动产生的现金流量净额-169,579,893.12-116,697,489.8-117,883,795.652,558,946,923.35
投资活动现金流入小计8,094,622,501.514,002,018,764.661,588,278,826.0811,591,098,222.9
投资活动现金流出小计7,223,161,040.384,154,577,327.542,134,856,961.8112,757,844,449.43
投资活动产生的现金流量净额871,461,461.13-152,558,562.88-546,578,135.73-1,166,746,226.53
筹资活动现金流入小计---15,571,000
筹资活动现金流出小计378,287,855.11378,694,190.54,518,018.83931,519,041.41
筹资活动产生的现金流量净额-378,287,855.11-378,694,190.5-4,518,018.83-915,948,041.41
汇率变动对现金及现金等价物的影响3,454,044.416,882,499.74-525,431.77-10,008,330.53
现金及现金等价物净增加额327,047,757.31-641,067,743.44-669,505,381.98466,244,324.88
期末现金及现金等价物余额3,426,097,883.742,457,982,382.992,429,544,744.453,099,050,126.43
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润2.98亿元,每股收益0.51元。

    截至第三季度最新股东权益742908.28万元,未分配利润512592.77万元。

    截至第三季度最新总资产830776.37万元,负债87868.09万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入632,543,388.93427,695,798.2195,173,984.726,450,356,637.86
营业总成本649,562,487.47432,733,363.67208,212,898.933,908,293,410.02
营业利润366,331,155.03111,377,767.2471,852,760.922,339,809,462.07
利润总额352,123,142.95108,045,667.9770,437,043.942,315,921,580.59
净利润298,485,079.7690,920,733.8559,989,487.461,936,706,879.02
其他综合收益-8,530,070.973,757,379.64-2,094,022.13-2,529,970.79
综合收益总额289,955,008.7994,678,113.4957,895,465.331,934,176,908.23
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计6,086,682,981.246,263,941,916.67,049,797,308.087,525,436,285.14
非流动资产合计2,221,080,746.551,978,619,359.151,677,257,425.561,648,325,798.6
资产总计8,307,763,727.798,242,561,275.758,727,054,733.649,173,762,083.74
流动负债合计771,773,768.27912,976,671.11,087,834,786.91,571,725,748.35
非流动负债合计106,907,167.1681,818,594.1364,976,658.889,263,740.65
负债合计878,680,935.43994,795,265.231,152,811,445.71,660,989,489
归属于母公司股东权益合计7,414,741,960.747,232,942,079.647,562,110,642.187,500,616,529.33
股东权益合计7,429,082,792.367,247,766,010.527,574,243,287.947,512,772,594.74
负债和股东权益合计8,307,763,727.798,242,561,275.758,727,054,733.649,173,762,083.74
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计1,350,241,899.62996,770,481.17567,398,702.136,493,768,113.71
经营活动现金流出小计1,519,821,792.741,113,467,970.97685,282,497.783,934,821,190.36
经营活动产生的现金流量净额-169,579,893.12-116,697,489.8-117,883,795.652,558,946,923.35
投资活动现金流入小计8,094,622,501.514,002,018,764.661,588,278,826.0811,591,098,222.9
投资活动现金流出小计7,223,161,040.384,154,577,327.542,134,856,961.8112,757,844,449.43
投资活动产生的现金流量净额871,461,461.13-152,558,562.88-546,578,135.73-1,166,746,226.53
筹资活动现金流入小计---15,571,000
筹资活动现金流出小计378,287,855.11378,694,190.54,518,018.83931,519,041.41
筹资活动产生的现金流量净额-378,287,855.11-378,694,190.5-4,518,018.83-915,948,041.41
汇率变动对现金及现金等价物的影响3,454,044.416,882,499.74-525,431.77-10,008,330.53
现金及现金等价物净增加额327,047,757.31-641,067,743.44-669,505,381.98466,244,324.88
期末现金及现金等价物余额3,426,097,883.742,457,982,382.992,429,544,744.453,099,050,126.43
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
戴立忠19004.2332.2918720.32
朱锦伟4449.227.56-587.00
湖南圣维投资管理有限公司3719.666.323719.66
陈文义3291.745.590.00
中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资基金988.471.68263.61
湖南圣维鼎立管理咨询中心(有限合伙)756.711.29756.71
湖南圣维华宁管理咨询中心(有限合伙)726.751.24726.75
刘欲晓639.961.090.00
香港中央结算有限公司500.570.85193.85
中国信达资产管理股份有限公司444.000.75-57.83
  主力控盘
  公司简介
圣湘生物 所属地域: 湖南省 涉及概念: 生物医药,抗原检测,基因测序,流感,猴痘概念,肝炎概念,沪股通,专精特新,融资融券
主营业务: 生物技术开发服务、咨询、交流服务、转让服务;一类医疗器械、二类医疗器械、三类医疗器械、通用仪器仪表、医药原料、医疗实验室设备和器具、医药辅料、塑料加工专用设备、配件、耗材、电子元件及组件、化学试剂及日用化学产品(不含危险及监控化学品)的销售;医疗用品及器材、电子产品、医疗诊断、监护及治疗设备的零售;一类医疗器械、二类医疗器械、三类医疗器械、Ⅱ类:6840体外诊断试剂的生产;Ⅱ类:6840体外诊断试剂、一类医疗器械、二类医疗器械的研发;医学检验技术服务;医疗器械技术推广服务。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
上市日期: 2020-08-28 每股净资产: 12.29元 每股收益: 0.16元 净利润: 0.92亿元 净利润增长率: -91.85%
营业收入: 4.28亿元 每股现金流: -0.20元 每股公积金: 3.28元 每股未分配利润: 8.36元 总股本: 5.88亿 流通股: 5.88亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心